High-dose chemotherapy and CD34-selected peripheral blood progenitor cell transplantation for patients with breast cancer metastatic to bone and/or bone marrow

Bone Marrow Transplantation

Volumn 28, Issue 11, 2001, Pages 1023-1029

  Klein, J L ^a   Hamm, C ^a   Dansey, R D ^a   Karanes, C ^a   Abella, E ^a   Cassells, L ^a   Peters, W P ^a   Baynes, R D ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD34; Immunomagnetic separation; Metastatic breast cancer; Peripheral blood progenitor cell transplantation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARMUSTINE; CD34 ANTIGEN; CIMETIDINE; CIPROFLOXACIN; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIFAMPICIN; STEROID; TOBRAMYCIN; VANCOMYCIN;

ADULT; ARTICLE; BACTERIAL INFECTION; BONE MARROW METASTASIS; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CELL SELECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; LEUKOCYTE COUNT; LUNG TOXICITY; MAJOR CLINICAL STUDY; MYCOSIS; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

ADULT; ANTHRACYCLINES; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL SEPARATION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PACLITAXEL; TAXOIDS; VINBLASTINE;

EID: 0035663625     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703274     Document Type: Article

References (35)

1. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
2. Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: Outcomes by intent to treat analyses
3. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group
4. Immunocytochemical detection of tumor cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer
5. Detection and clinical importance of micrometastatic disease
6. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver
7. Peripheral blood stem cell transplantation
8. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor
9. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone
10. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow
11. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation
12. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma
13. Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma
14. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer
15. Clinical toxicity of cryopreserved circulating progenitor cells infusion
16. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy
17. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells
18. + peripheral blood progenitor cells
19. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer
20. Outcome of primary-breast cancer patients with micrometastases: A long-term follow-up study
21. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support
22. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
23. Detection of tumor cells in bone marrow of patients with primary breast cancer: A prognostic factor for distant metastasis
24. + selection to clinical outcome
25. + peripheral blood cells selected using a fully automated immunomagnetic system in patients with high-risk breast cancer: Results of a prospective randomized multicenter clinical trial
26. Improved survival with consolidation high-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) compared with observation in women with metastatic breast cancer (MBC) and only bone metastases treated with 5-fluorouracil and methotrexate (AFM): A phase III prospective randonized comparative trial
27. Immune reconstitution following bone marrow transplantation: Comparison of recipients of T-cell depleted marrow with recipients of conventional marrow grafts
28. + cell transplantation
29. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
30. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation
31. Cytomegalovirus infection after autologous bone marrow transplantation: Occurrence of cytomegalovirus disease and effect on engraftment
32. Ex vivo expansion of megakaryocyte progenitors: Effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood
33. Varicella zoster virus infections following allogeneic bone marrow transplantation: Frequency, risk factors, and clinical outcome
34. Varicella zoster virus infection associated with high-dose chemotherapy and autologous stem cell rescue
35. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation